Why Diabetic Nerve Pain Burns at Night — and Why the Same Foot Feels Nothing

What this video covers

• How high glucose, abnormal lipids, and small-vessel injury are thought to injure the longest nerves first, and why that mechanism is still largely preclinical
• Why small fibers fail first (burning) and large fibers later (numbness, imbalance), and why numb feet need daily inspection to prevent ulcers and amputation
• What glucose control can and cannot do: it prevents new neuropathy in type 1 diabetes, was not significant in type 2, does not reverse established damage, and raises hypoglycemia risk
• What the 2022 American Academy of Neurology guideline recommends, why it recommends against opioids, and which drugs are off-label
• When 10 kHz spinal cord stimulation fits refractory pain, what the randomized data showed, and what the trial did not prove
• MEDICAL DISCLAIMER: This content is for educational purposes only and is not medical advice. It does not substitute for professional diagnosis or treatment. Always consult a licensed healthcare provider regarding your condition. Viewing this video does not establish a doctor-patient relationship.

It starts at night. The sheet touches your toes and it burns. Your socks feel like sandpaper. You put your hand on your feet and the skin tells you nothing — ordinary, unremarkable, sometimes cool. The fire is on the inside, where your hand cannot reach it.

And then there is the part nobody explains: the burning is unbearable, yet you can cross gravel and never feel it. Exquisite pain and dead numbness, in the same foot, at the same moment. That is not a contradiction. It is a signature. This article explains what is physically happening inside the nerve, why it produces exactly that pair of symptoms, what a fifteen-minute prescription visit tends to miss, and what an honest evaluation looks like.

The length of the wire is the whole disease

Diabetic peripheral neuropathy is a length-dependent, dying-back axonopathy. In plain language: it fails at the far end of the wire first, and it works its way backward toward the source.

Consider what your body is actually asking of these cells. The longest axons you own belong to sensory nerve cells whose bodies sit in the ganglia just outside your lumbar spine, and whose fibers run all the way down to your great toe — close to a meter of living membrane that one single cell has to build, supply, maintain, and power from a distance. The far end of that wire is the hardest part of the cell to supply, and it is the first place to go dark.

That geometry also predicts what happens next. When the numbness has climbed to roughly your knees, your fingertips are next in line — because that is the point at which the remaining leg axon and the axon running out to your fingertip are about the same length. That is when the hands begin, and the pattern becomes what clinicians call stocking and glove.

What we know about why the nerve fails — and how confident we are

Here the honesty matters. In preclinical models, high glucose and abnormal lipids drive polyol flux, advanced glycation end-products, oxidative stress, and injury to the vasa nervorum — the tiny blood vessels that feed the nerve itself. That work remains preclinical, and it has produced no approved disease-modifying therapy for human diabetic neuropathy. It is a mechanistic picture, not a treatment target you can act on today.

Pain that persists after glucose is well controlled is generally attributed to central sensitization — the nervous system amplifying signals after prolonged injury. That is a reasonable inference. It is not a measured fact in any individual patient.

Why burning and numbness live in the same foot

Your peripheral nerves are not one wire. They are bundles of different fiber types, and they do not fail on the same schedule.

Small fibers fail first. These are the unmyelinated C fibers and the thinly myelinated A-delta fibers, and they carry burning, temperature, and pinprick. When they degenerate, you get burning, and you get allodynia — a bedsheet, an ordinary and harmless thing, read by the nervous system as an injury. That is why bedding is so often the trigger people describe, and why the symptom is most often reported at night, when the feet are still and in contact with the sheet.

Large myelinated fibers fail later. These carry touch, vibration, and joint position sense — the ordinary awareness of where your foot is. When they go, you get numbness, loss of vibration and position sense, and unsteadiness in the dark, when your eyes can no longer compensate for what your feet stopped reporting.

Because the small fibers go first and the large fibers go later, there is a long window in which both processes are running in the same foot. That is the “burning but numb” experience — a recognized signature of the condition, not an exaggeration on your part.

The numbness also carries the practical danger in this condition. A foot that cannot feel a pebble will not report an ulcer until that ulcer is deep, and an unnoticed ulcer is how people lose limbs. Numb feet need to be looked at — every day by you, and at every visit by your physician. Daily inspection is how you keep your leg.

What the prescription-only approach misses

What most people with these feet get is a prescription and a shrug. Gabapentin at 300 mg, then 900, then 1800, and when that fails, more.

What frequently does not happen in that same fifteen minutes:

• Nobody checks B12 or thyroid function. Either can produce a neuropathy that imitates the diabetic pattern.
• Nobody sends a serum protein electrophoresis with immunofixation to look for a monoclonal gammopathy. Electrophoresis alone is not sufficient, because small clones hide from it — and that neuropathy looks identical from across the room while belonging in a different clinic entirely.
• Nobody asks honestly about alcohol, or examines the lumbar spine for a compressed nerve root, which can mimic or coexist with the diabetic pattern.
• Nobody takes your shoes off.

There is one more gap worth naming. When gabapentin fails, the next step offered is too often an opioid — which the 2022 American Academy of Neurology guideline specifically recommends against for painful diabetic polyneuropathy (a Level B recommendation not to use them).¹

None of this is a criticism of the medications themselves. Drug therapy has a legitimate place here, and the 2022 AAN guideline supports four drug classes for this condition.¹ But it is symptomatic: the benefit lasts only while you take the drug, and it does nothing about the state of the nerve. The failure is not the prescription. The failure is the workup that never happened around it.

And the thing you were told about blood sugar

You have probably been told that getting your sugar down resolves this. The evidence is narrower than that, and it deserves to be stated precisely.

A 2012 Cochrane review — which has never been updated — found that enhanced glucose control prevents new neuropathy in type 1 diabetes, on high-quality evidence. In type 2 diabetes, the reduction did not reach statistical significance. And critically, that evidence is about preventing neuropathy, not about reversing damage you already have. The same review found that intensive glucose lowering significantly increases severe hypoglycemic episodes.²

So: glucose control remains the only intervention with any disease-modifying evidence behind it, and it is worth pursuing — pursued to a target your diabetes physician sets for you, not to the lowest number you can force. Intensive lowering has its own real harms. You deserve to know what glucose control buys you and what it does not.

What this means for evaluation and treatment

Take your shoes off, because that is where this starts. Nothing gets injected into a spine and nothing gets implanted until the stocking pattern on your own feet has been mapped by hand and the conditions that imitate it have been ruled out on paper.

A real workup includes:

• Confirmed diabetes, and a length-dependent, symmetric distribution on physical examination — 10 g monofilament, 128 Hz tuning fork, pinprick, ankle reflexes, proprioception.
• Electrodiagnostic testing where it changes the answer. An important limitation: nerve conduction studies read large fibers, and can be entirely normal in a pure small-fiber neuropathy.
• A 3 mm skin punch biopsy from the distal leg when the exam says small fiber and the conduction study says normal. It settles the question by counting the nerve fibers in your own epidermis.
• Exclusion of the mimics: B12 deficiency, thyroid disease, monoclonal gammopathy, alcohol, and lumbosacral radiculopathy.
• Foot inspection at every visit, for the reason described above.

On medications, know which is which. The 2022 AAN guideline offers four classes: tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and sodium channel blockers. Tricyclics showed the largest effect size — at low confidence, which is worth saying out loud rather than burying.¹ Only pregabalin, duloxetine, tapentadol extended release, and the 8% capsaicin patch are FDA-approved for this indication; gabapentin, amitriptyline, nortriptyline, venlafaxine, and the sodium channel blockers are used off-label — legitimate and evidence-informed, and off-label. And the uncomfortable part: tapentadol carries an FDA approval here and a Level B recommendation against it from that same guideline.

The risks are specific, not generic. Gabapentinoids need renal dose reduction, and cause sedation, ankle swelling, weight gain, and falls, with serious respiratory risk alongside other sedatives. Tricyclics carry cardiac conduction effects, so cardiac history and an ECG come first, plus anticholinergic effects and orthostatic drops. Antidepressants and antiseizure drugs carry suicidality warnings. Do not start, stop, or change any medication without consulting your physician.

When pain stays severe after a gabapentinoid plus one other class for a year or longer, high-frequency spinal cord stimulation becomes a reasonable conversation. Under live fluoroscopy, two eight-contact percutaneous leads are placed through an interlaminar approach into the posterior epidural space, spanning the eighth through eleventh thoracic vertebral bodies, over the dorsal columns that carry sensation from the feet and legs. You do a one-week trial first, with the leads externalized through the skin — if it does not deliver, nothing is implanted and the leads come out. You can read how the procedure itself is performed and staged on our diabetes and neuropathy treatment page.

What the data show, stated with its limits: in a randomized trial published in JAMA Neurology in 2021, 79% of participants on 10 kHz stimulation plus conventional management reached at least 50% pain relief without worsening of neurological deficits at three months, versus 5% on conventional management alone.³ That trial was open-label and not sham-controlled, and the control arm crossed over at six months, so anything past that point is uncontrolled. Enrollment required an HbA1c of 10% or less, a BMI of 45 or less, pain of at least 5 out of 10, and no active foot ulcer — if you do not resemble that group, the numbers may not describe you. The FDA approval here is device-specific, not a class approval. Individual results vary; these are trial averages, not a promise about your feet.

The risks are real: infection requiring device removal — about 2% in that trial, and likelier with diabetes — lead migration, epidural hematoma, dural puncture, hardware failure, and loss of effect over time.

Adjuncts, labeled honestly. Ketogenic nutrition, specialized pro-resolving mediators, and photobiomodulation are adjunctive, off-label, and unproven for diabetic neuropathy. If you want to try one, the right way to do it is with a fixed trial window and a stopping rule agreed before you start, and a willingness to stop if nothing changes. That is an optional adjunct with a deadline. It is not treatment for your neuropathy and should not be sold to you as one.

An honest picture of what “better” looks like

The following is a composite — a picture assembled from many patients with this condition, not one person’s chart. Years of burning feet. Gabapentin pushed to the ceiling, then duloxetine, then a tricyclic stopped early when the ECG showed a conduction delay. Months of work with the primary team to bring an HbA1c into range for candidacy. A stimulator trial that was awkward and inconvenient, including keeping a dressing dry for a full week without a shower — and in the randomized trial described above, roughly one participant in five did not reach the response threshold at three months, which is precisely what the trial period exists to find out.³

In this composite, relief did come, and it was substantial but partial. The burning quieted. Sleep returned. The numbness did not reverse — large-fiber loss does not undo itself, which is why the daily foot check continued. That is not a cure. That is a person who got their nights back and kept both feet. Individual results vary.

Frequently asked questions

Key takeaways

• Diabetic peripheral neuropathy is a length-dependent, dying-back axonopathy: the longest nerve fibers, running from the lumbar ganglia to the great toe, fail at the far end first.
• Small fibers degenerate before large ones, which is why burning pain and dead numbness coexist in the same foot — and why an insensate foot needs daily inspection to prevent an unnoticed ulcer.
• Glucose control has disease-modifying evidence for preventing new neuropathy in type 1 diabetes only, was not statistically significant in type 2, does not reverse existing damage, and raises severe hypoglycemia risk.
• Drug therapy is symptomatic and works only while taken; several commonly used agents are off-label, and the 2022 AAN guideline recommends against opioids here.
• For pain refractory to a gabapentinoid plus one other class for a year or more, 10 kHz spinal cord stimulation has randomized but open-label, non-sham-controlled evidence, real device risks, and a one-week trial before any implant.

Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. If your feet burn at night, or you have stopped feeling the floor, call (314) 481-5000 or text (314) 886-5902 to arrange a full neuropathy evaluation.

References

1. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021;78(6):687-698. PMID 33818600. PubMed
2. Price R, Smith D, Franklin G, et al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee. Neurology. 2022;98(1):31-43. PMID 34965987. PubMed
3. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;2012(6):CD007543. PMID 22696371. PubMed

Dr. Gurpreet Singh Padda, MD, MBA, MHP